BioAlliance’s Sitavig debuts in USA; new patent granted

22 July 2014

French drug developer BioAlliance Pharma (Euronext Paris: BIO) says that its US partner Innocutis Holdings has launched Sitavig (acyclovir Lauriad) in the USA and announced the granting of a new US Sitavig patent by the US Patent and Trademark Office.

A few weeks after the execution of a licensing agreement between the two companies, Innocutis has begun the promotion of Sitavig in the USA for the treatment of labial herpes to dermatologists and top tier general practitioners.

Herpes labialis is an extremely widespread condition. Between 20% and 40% of the adult population suffer from recurrent cold sores, namely from 60 to 120 million people in the USA, representing a market potential from $400 million to $500 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK